Please assess the completion status of the following clinical trial:

Trial Title: The Ranibizumab Plus Transpupillary Thermotherapy for Neovascular Age-Related Macular Degeneration (AMD) Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients with subfoveal neovascular AMD with either classic/predominantly classic or occult lesions~* visual acuity =\> 20/200~Exclusion Criteria:~* subretinal fibrosis or atrophy under the fovea~* patients previously treated for neovascular AMD in the study eye

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TTT (Type: ACTIVE_COMPARATOR): TTT is given every three months
- Sham TTT (Type: SHAM_COMPARATOR): Sham TTT is given every three months

Based on this trial design, predict the completion outcome and termination type (if applicable).